Related Experiment Videos
[A new approach to pharmacogenomics]
1Research Division, Glaxo Wellcome K.K., Ibaraki, Japan.
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
|October 14, 2000
Summary
Pharmacogenomics, the study of genes influencing drug response, will revolutionize medicine by enabling "right drug to right patient" treatments. This genomic approach will minimize clinical trial risks and transform drug discovery from target identification to late-stage development.
Area of Science:
- Genomics
- Pharmacology
- Bioinformatics
Context:
- 21st-century medicine is shifting towards evidence-based and personalized approaches.
- Pharmacogenomics integrates genetic information to determine drug efficacy and patient sensitivity.
- The principle of 'right drug to right patient' is central to modern therapeutics.
Purpose:
- To outline the predicted impact of pharmacogenomics on healthcare and drug discovery.
- To describe the three anticipated waves of genomic influence in medicine.
- To highlight the key technologies driving the pharmacogenomics era.
Summary:
- Pharmacogenomics analyzes genes affecting drug behavior and sensitivity, promising significant healthcare and drug discovery advancements.
- Three waves of genomic impact are expected: minimizing clinical trial risks, refining early-stage candidate selection, and advancing disease gene discovery.
- Key technologies include Single Nucleotide Polymorphism (SNP) databases, differential gene expression (DGE) analysis, proteomics, Serial Analysis of Gene Expression (SAGE), and bioinformatics.
Impact:
- Pharmacogenomics will minimize risks in clinical trials, such as adverse events and drug resistance.
- It will optimize drug candidate selection in early development phases.
- The integration of genomics, proteomics, and structural genomics will redefine disease target discovery and drug development.